Phaeohyphomycosis: A dark question mark in clinical disease

Journal of Invasive Fungal Infections

Volumn 3, Issue 3, 2009, Pages 82-88

  Al Abdely, Hail M ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCYTOSINE; ITRACONAZOLE; MELANIN; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; BRAIN INFECTION; FUNGAL VIRULENCE; FUNGUS CULTURE; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; LABORATORY DIAGNOSIS; NONHUMAN; PHAEOHYPHOMYCOSIS; PNEUMONIA; REVIEW; SINUSITIS; SYSTEMIC MYCOSIS; TAXONOMY;

EID: 83455260005     PISSN: 17533783     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Li DM, de Hoog GS. Cerebral phaeohyphomycosis - a cure at what lengths? Lancet Infect Dis 2009;9:376-83.
2. Brandt ME, Warnock DW. Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J Chemother 2003;15(Suppl 2):36-47. (Pubitemid 38021614)
3. Matsumoto T, Ajello L, Matsuda T et al. Developments in hyalohyphomycosis and phaeohyphomycosis. J Med Vet Mycol 1994;32(Suppl 1):329-49.
4. Ajello L, Georg LK, Steigbigel RT et al. A case of phaeohyphomycosis caused by a new species of Phialophora. Mycologia 1974;66:490-8.
5. Ahmed AA, van de Sande WW, Fahal A et al. Management of mycetoma: major challenge in tropical mycoses with limited international recognition. Curr Opin Infect Dis 2007;20:146-51. (Pubitemid 46340796)
6. Milam CP, Fenske NA. Chromoblastomycosis. Dermatol Clin 1989;7:219-25. (Pubitemid 19102933)
7. Jacobson ES. Pathogenic roles for fungal melanins. Clin Microbiol Rev 2000;13:708-17.
8. Szaniszlo P. Virulence factors in black molds with emphasis on melanin, chitin, and Wangiella as a molecularly tractable model. In: Heitman J, editor, Molecular principles of fungal pathogenesis. Washington, DC: ASM, 2006, pp 407-28.
9. Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004;38:206-16. (Pubitemid 38113028)
10. Geis PA, Wheeler MH, Szaniszlo PJ. Pentaketide metabolites of melanin synthesis in the dematiaceous fungus Wangiella dermatitidis. Arch Microbiol 1984;137:324-8. (Pubitemid 14143480)
11. Taylor BE, Wheeler MH, Szaniszlo PJ. Evidence for pentaketide melanin biosynthesis in dematiaceous human pathogenic fungi. Mycologia 1987;79:320-2.
12. Elies L, Balandraud V, Boulouha L et al. Fatal systemic phaeohyphomycosis in a cat due to Cladophialophora bantiana. J Vet Med A Physiol Pathol Clin Med 2003;50:50-3.
13. Al-Abdely HM. Management of rare fungal infections. Curr Opin Infect Dis 2004;17:527-32. (Pubitemid 39627513)
14. Al-Abdely HM, Alkhunaizi AM, Al-Tawfiq JA et al. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med Mycol 2005;43:91-5. (Pubitemid 40192606)
15. Segner S, Jouret F, Durant JF et al. Cutaneous infection by Alternaria infectoria in a renal transplant patient. Transpl Infect Dis 2009;11:330-2.
16. Lin SC, Sun PL, Ju YM et al. Cutaneous phaeohyphomycosis caused by Exserohilum rostratum in a patient with cutaneous T-cell lymphoma. Int J Dermatol 2009;48:295-8.
17. Kumar KK, Hallikeri K. Phaeohyphomycosis. Indian J Pathol Microbiol 2008;51:556-8.
18. Revankar SG, Patterson JE, Sutton DA et al. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002;34:467-76. (Pubitemid 34121028)
19. Ben-Ami R, Lewis RE, Raad II et al. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 2009;48:1033-41.
20. Proia LA, Hayden MK, Kammeyer PL et al. Phialemonium: an emerging mold pathogen that caused 4 cases of hemodialysis-associated endovascular infection. Clin Infect Dis 2004;39:373-9. (Pubitemid 39050486)
21. Pauzner R, Goldschmied-Reouven A, Hay I et al. Phaeohyphomycosis following cardiac surgery: case report and review of serious infection due to Bipolaris and Exserohilum species. Clin Infect Dis 1997;25:921-3. (Pubitemid 27443867)
22. Naggie S, Perfect JR. Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis. Clin Chest Med 2009;30:337-53, vii-viii.
23. Bartynski JM, McCaffrey TV, Frigas E. Allergic fungal sinusitis secondary to dermatiaceous fungi - Curvularia lunata and Alternaria. Otolaryngol Head Neck Surg 1990;103:32-9. (Pubitemid 20226128)
24. Schubert MS. Allergic fungal sinusitis: pathophysiology, diagnosis and management. Med Mycol 2009;47(Suppl 1):S324-30.
25. Seiberling K, Wormald PJ. The role of itraconazole in recalcitrant fungal sinusitis. Am J Rhinol Allergy 2009;23:303-6.
26. Lake FR, Froudist JH, McAleer R et al. Allergic bronchopulmonary fungal disease caused by Bipolaris and Curvularia. Aust N Z J Med 1991;21:871-4.
27. Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol 2004;15:321-7. (Pubitemid 38962112)
28. McGinnis MR. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol 1983;8:1-16. (Pubitemid 13221132)
29. Kimura M, McGinnis MR. Fontana-Masson - stained tissue from culture-proven mycoses. Arch Pathol Lab Med 1998;122:1107-11. (Pubitemid 29009405)
30. Dixon DM, Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy 1987;33:129-40. (Pubitemid 17017093)
31. McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol 1998;36:2353-5. (Pubitemid 28324097)
32. Fothergill AW, Rinaldi MG, Sutton DA. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole. Med Mycol 2009;47:41-3.
33. McGinnis MR, Pasarell L. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med Mycol 1998;36:243-6.
34. Odabasi Z, Paetznick VL, Rodriguez JR et al. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother 2004;48:1912-5. (Pubitemid 38544413)
35. Al-Abdely HM, Najvar L, Bocanegra R et al. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). Antimicrob Agents Chemother 2000;44:1159-62. (Pubitemid 30228288)
36. Al-Abdely HM, Najvar LK, Bocanegra R et al. Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob Agents Chemother 2005;49:1701-7. (Pubitemid 40631577)
37. Graybill JR, Najvar LK, Johnson E et al. Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob Agents Chemother 2004;48:2288-91. (Pubitemid 38691633)
38. Rivard RG, McCall S, Griffith ME et al. Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection. Med Mycol 2007;45:685-9. (Pubitemid 350153960)
39. Dixon DM, Walsh TJ, Merz WG et al. Infections due to Xylohypha bantiana (Cladosporium trichoides). Rev Infect Dis 1989;11:515-25.
40. Lirng JF, Tien RD, Osumi AK et al. Cerebral phaeohyphomycosis complicated with brain abscess: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 1995;55:491-5.
41. Safdar A. Curvularia - favorable response to oral itraconazole therapy in two patients with locally invasive phaeohyphomycosis. Clin Microbiol Infect 2003;9:1219-23. (Pubitemid 38028872)
42. Halaby T, Boots H, Vermeulen A et al. Phaeohyphomycosis caused by Alternaria infectoria in a renal transplant recipient. J Clin Microbiol 2001;39:1952-5. (Pubitemid 32417050)
43. Trinh JV, Steinbach WJ, Schell WA et al. Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. Med Mycol 2003;41:339-45. (Pubitemid 37059214)
44. Hollingsworth JW, Shofer S, Zaas A. Successful treatment of Ochroconis gallopavum infection in an immunocompetent host. Infection 2007;35:367-9. (Pubitemid 47502342)
45. Negroni R, Helou SH, Petri N et al. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 2004;38:e15-20.
46. Rallis E, Frangoulis E. Successful treatment of subcutaneous phaeohyphomycosis owing to Exophiala jeanselmei with oral terbinafine. Int J Dermatol 2006;45:1369-70. (Pubitemid 44688040)
47. Safdar A. Antifungal immunity and adjuvant cytokine immune enhancement in cancer patients with invasive fungal infections. Clin Microbiol Infect 2007;13:1-4. (Pubitemid 44869201)